TheEdgeResearch
Home / Stocks / XERS

Xeris Biopharma Holdings, Inc. (XERS)

NASDAQ Healthcare Biotechnology
$6.16 ▼ -2.53%
Market Cap
$1.06B
Sector
Healthcare
Industry
Biotechnology
Beta
0.92
52-Wk Range
4.3-10.08
CEO
John Shannon
Country
US
Currency
USD

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development progra…

Open full interactive analysis & DCF →